Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Liminatus Pharma ( (LIMN) ) just unveiled an announcement.
On November 19, 2025, Liminatus Pharma, Inc. received notifications from Nasdaq indicating non-compliance with certain listing rules due to insufficient market value of listed securities and publicly held shares. The company has been given until May 18, 2026, to regain compliance, failing which it may face delisting or consider transferring to the Nasdaq Capital Market. The company is actively working to meet the requirements, but there is no assurance of success within the given timeframe.
More about Liminatus Pharma
Liminatus Pharma, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of pharmaceutical products.
Average Trading Volume: 739,764
Technical Sentiment Signal: Sell
Current Market Cap: $22.81M
Learn more about LIMN stock on TipRanks’ Stock Analysis page.